Clinical integration of significant CRISPR marker genes across ADE drugs in pAML cohorts treated with only ADE regimen. (A) All significant CRISPR signature marker genes for each drug with 3748 unique genes were further investigated in 3 independent pAML cohorts treated with ADE to determine the association between diagnostic gene expression and clinical outcomes (EFS, OS, and MRD1). (B) Each gene was evaluated to determine whether sensitive markers from CRISPR results with high expression led to beneficial (HR/OR <1) or resistant markers from CRISPR results with high expression led to detrimental outcomes (HR/OR >1) in all 3 clinical cohorts. Collectively, these marker genes were deemed to be biologically important genes with prognostic potential. (C) Significant markers genes with CRISPR screens and at least 1 significant clinical outcome in pAML cohorts treated with ADE either with or without risk adjustment. Significant outcomes were defined as P value < .05 in HR or OR.